Literature DB >> 7580798

Use of synthetic peptides to identify surface-exposed, linear B-cell epitopes within outer membrane protein F of Pseudomonas aeruginosa.

H E Gilleland1, E E Hughes, L B Gilleland, J M Matthews-Greer, J Staczek.   

Abstract

In a previous study (Hughes EE, Gilleland LB, Gilleland HE Jr. [1992] Infect Immun 60:3497-3503), ten synthetic peptides were used to test for surface-exposed antigenic regions located throughout the length of outer membrane protein F of Pseudomonas aeruginosa. An additional nine peptides of 11-21 amino acid residues in length were synthesized. Antisera collected from mice immunized with each of the 19 synthetic peptides conjugated to keyhole limpet hemocyanin were used to determine which of the peptides had elicited antibodies capable of reacting with the surface of whole cells of the various heterologous Fisher-Devlin immunotypes of P. aeruginosa. Cell surface reactivity was measured by an enzyme-linked immunosorbent assay (ELISA) with whole cells of the various immunotypes as the ELISA antigens and by opsonophagocytic uptake assays with the various peptide-directed antisera, immunotype 2 P. aeruginosa cells, and polymorphonuclear leukocytes of human and murine origin. Three peptides located in the carboxy-terminal portion of protein F elicited antibodies with the greatest cell-surface reactivity. Peptide 9 (TDAYNQKLSERRAN), peptide 10 (NATAEGRAINRRVE), and peptide 18 (NEYGVEGGRVNAVG) appear to have sufficient potential for further development as vaccine candidates for immunoprophylaxis against infections caused by P. aeruginosa. A topological model for the arrangement of protein F within the outer membrane of P. aeruginosa is presented.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7580798     DOI: 10.1007/BF00314580

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  31 in total

1.  Immunotherapeutic potential of monoclonal antibodies against Pseudomonas aeruginosa protein F.

Authors:  R E Hancock; L M Mutharia; E C Mouat
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

2.  Use of monoclonal antibodies to protein F of Pseudomonas aeruginosa as opsonins for phagocytosis by macrophages.

Authors:  J L Battershill; D P Speert; R E Hancock
Journal:  Infect Immun       Date:  1987-10       Impact factor: 3.441

3.  Synthetic peptides: a next generation of vaccines?

Authors:  M W Steward; C R Howard
Journal:  Immunol Today       Date:  1987

4.  A thermodynamic scale for the beta-sheet forming tendencies of the amino acids.

Authors:  C K Smith; J M Withka; L Regan
Journal:  Biochemistry       Date:  1994-05-10       Impact factor: 3.162

5.  Prediction of transmembrane beta-strands from hydrophobic characteristics of proteins.

Authors:  M M Gromiha; P K Ponnuswamy
Journal:  Int J Pept Protein Res       Date:  1993-11

6.  Epitope mapping of the Pseudomonas aeruginosa major outer membrane porin protein OprF.

Authors:  E G Rawling; N L Martin; R E Hancock
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

7.  Synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa that elicit antibodies reactive with whole cells of heterologous immunotype strains of P. aeruginosa.

Authors:  E E Hughes; L B Gilleland; H E Gilleland
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

8.  Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model.

Authors:  H E Gilleland; L B Gilleland; J M Matthews-Greer
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

9.  Surface localization of Pseudomonas aeruginosa outer membrane porin protein F by using monoclonal antibodies.

Authors:  L M Mutharia; R E Hancock
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

10.  Vaccine efficacies of elastase, exotoxin A, and outer-membrane protein F in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model.

Authors:  H E Gilleland; L B Gilleland; M R Fowler
Journal:  J Med Microbiol       Date:  1993-02       Impact factor: 3.196

View more
  6 in total

1.  Pseudomonas aeruginosa porin OprF exists in two different conformations.

Authors:  Etsuko Sugawara; Ekaterina M Nestorovich; Sergey M Bezrukov; Hiroshi Nikaido
Journal:  J Biol Chem       Date:  2006-04-04       Impact factor: 5.157

2.  Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.

Authors:  Stefan Worgall; Anja Krause; Michael Rivara; Kyung-Kim Hee; Enrico V Vintayen; Neil R Hackett; Peter W Roelvink; Joseph T Bruder; Thomas J Wickham; Imre Kovesdi; Ronald G Crystal
Journal:  J Clin Invest       Date:  2005-04-01       Impact factor: 14.808

3.  Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.

Authors:  E Mansouri; J Gabelsberger; B Knapp; E Hundt; U Lenz; K D Hungerer; H E Gilleland; J Staczek; H Domdey; B U von Specht
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

4.  The C-terminal domain of Salmonella enterica serovar typhimurium OmpA is an immunodominant antigen in mice but appears to be only partially exposed on the bacterial cell surface.

Authors:  Shiva P Singh; Yvonne U Williams; Stephanie Miller; Hiroshi Nikaido
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

5.  A chimeric influenza virus expressing an epitope of outer membrane protein F of Pseudomonas aeruginosa affords protection against challenge with P. aeruginosa in a murine model of chronic pulmonary infection.

Authors:  J Staczek; H E Gilleland; L B Gilleland; R N Harty; A García-Sastre; O G Engelhardt; P Palese
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

6.  Cell-free expression of the outer membrane protein OprF of Pseudomonas aeruginosa for vaccine purposes.

Authors:  Géraldine Mayeux; Landry Gayet; Lavinia Liguori; Marine Odier; Donald K Martin; Sandra Cortès; Béatrice Schaack; Jean-Luc Lenormand
Journal:  Life Sci Alliance       Date:  2021-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.